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Clinical syndrome due to immune restoration (IRS) are 
reported during the treatment of tuberculosis in HIV - 
infected patients after introduction of antiretroviral 
treatment (ART). However, the predictive factors of 
their appearance are poorly known, and their diagnosis 
and treatment are difficult. We studied IRS in HIV- 
infected patients treated for tuberculosis, hospitalized in 
our department between March, 1996 and December, 
1999. IRS was defined by: appearance or the appearance 
of fever, increase of the size of tuberculosis lesions or 
appearance of other localization of tuberculosis during 
antituberculous treatment (ATT). 
Twenty eight patients were studied, 9 patients with IRS 
(group I) and 19 pa t ients without IRS (group II). There 
was no difference between the groups I and II 
concerning age, sex ratio, HIV risk factor. On the other 
hand, 6/9 patients (group I) vs 2119 patients (group II) 
were native of a country of the intertropical regions 
(among which 4/9 vs l/19 of sub-Saharan Africa). 
Disseminated tuberculosis were more frequent in the 
group I (S/9) than in the group II (12/19) as well as 
positive sputum-smear examination: 6/9 patients (group 
I) vs 2/19 patients (group II). The mean number of CD4 
cells was comparable in the 2 groups as well as plasmatic 
HIV -RNA. None of the patients of the group I were 
receiving ART before AIT. In contrast, 1109 patients of 
the group II were receiving ART among which 6/11 in 
association with a protease inhibitor (PI), before ATT. 
All the patients of the group I were receiving ART 
(among which 7/9 with PI) initiated a mean of 32 days 
after the introduction of ATT. Among the 8 patients of 
the group II not treated by ART before tuberculosis, 6 
received a treatment by ART (among which 5/6, with PI) 
initiated a mean of 25 days after the introduction of 
ATT. The IRS noticed at all the patients of the group I 
appeared a mean of 13 days after the beginning of ART 
in the 7 patients with PI containing treatment. 
The IRS during tuberculosis seems more frequent in 
the patients native of intertropical regions of which sub- 
Saharian Africa and when the treatment by ART is 
initiated after the beginning of ATT, these two factors 
being possibly related. 
Vaginal microbicides 
Frank Mukonde 
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Hypothesis and background: The study was done on the 
hypothesis the that use of vaginal microbicides has little 
attention as a means of reducing the contraction of 
STDs and HIV 
Method: Fifty respondents aged between 15 and 49 years 
answered an anonymous questionnaire, answered 
questions during a focus group discussion. 
Results: Fifty per cent of the respondents who were 
sexually active had no knowledge about vaginal micro- 
bicides. Other means like condoms were used by 495 
because they believed microbicides like PRO 2000, D2S 
and N9 were toxic and produced unwelcome dryness. 
Forty per cent were able to define what a microbicide is, 
but could not give a specific example. 
Conclusion: There is need for more awareness cam- 
paigns on the use of vaginal microbicides especially with 
the increase in STDs and HIV/AIDS being observed 
in the 15 to 49 years age group. Microbicides have an 
additive effect on the reduction of HIV transmission, 
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(HUVEC) 
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HMGB-1 is a 219-amino acid protein and has over 98% 
sequence identity between rodents and humans. It has 
at least two basic structural units termed HMGB 
domains A and B. The protein has previously been 
described as a non-histone DNA binding protein. 
Recently HMGB-1 was identified as a pro inflammatory 
cytokine in stimulation of peripheral blood mono- 
nuclear cell cultures and as a late mediator of septic 
shock in mice. Our objective was to investigate whether 
HMGB-1 activates endothelial cells using 2nd-3rd 
passage HUVEC. Recombinant HMGB-1 was expressed 
in E. coli and purified to homogenity. HUVEC were 
grown to confluency and incubated with HMGB-1 at 
various concentrations. 
Results: Stimulation of HUVEC with HMGB-1 (100 ng- 
5 j.tg/ml) led to a dose dependent increase in adhesion 
of neutrophils and a concurrent increase in cell surface 
expression of ICAM-1, VCAM and E-selectin. This 
increase was observed after 16 h of incubation. Further, 
HMGB-1 induced a.release of both IL-S and granulocyte 
colony-stimulating factor. 
Conclusion: HMGB-1 activates HUVEC. This may have 
implication both in severe bacterial infection as well as 
in state of inflammatory disease. 
